# Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

> **NCT07166419** · PHASE1 · RECRUITING · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Recurrent Indolent Non-Hodgkin Lymphoma
- Recurrent Lymphoblastic Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Transformed Chronic Lymphocytic Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Refractory Indolent Non-Hodgkin Lymphoma
- Refractory Lymphoblastic Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Transformed Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** Autologous Anti-CD19/CD20/CD22 CAR T-cells
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Echocardiography Test
- **DRUG:** Fludarabine
- **PROCEDURE:** Multigated Acquisition Scan
- **PROCEDURE:** Pheresis
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT07166419
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-14
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07166419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07166419, "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07166419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*